Matthew V. Anderson

Matthew V. Anderson is a partner at Rakoczy Molino Mazzochi Siwik LLP (RMMS), where his practice focuses on intellectual property litigation, primarily emphasizing patent infringement suits under the Hatch-Waxman Amendments and the Biologics Price Competition and Innovation Act (BPCIA). His expertise spans small molecules, biologics, and general patent litigation, bolstered by a Master of Science in biotechnology. While his firm is highly regarded for its work in the biopharma sector, he also handles broader life sciences and medical device matters, as evidenced by his appearance in Haemonetics Corporation v. Fresenius Kabi USA, LLC et al., a case involving medical technology.

Anderson primarily represents generic pharmaceutical manufacturers and has a strong track record defending operating companies. His experience includes successfully representing Apotex Inc. and Apotex Corp. against Merck Sharp & Dohme Corp. in patent litigation concerning NASONEX®, with the Federal Circuit affirming a decision of non-infringement. He also secured favorable outcomes for Lupin Ltd. and Lupin Pharmaceuticals, Inc. in a patent dispute over TRIZIVIR®, and for Sandoz Inc. in Hatch-Waxman litigation related to COPAXONE®, where asserted claims were found non-infringed and/or invalid.

Beyond district court proceedings, Anderson possesses significant experience with inter partes review (IPR) petitions, including preparation, discovery, and oral arguments before the Patent Trial and Appeal Board (PTAB). He is admitted to practice in Illinois, before the U.S. Patent and Trademark Office, and the Federal Circuit Court of Appeals, as well as the U.S. District Court for the Northern District of Illinois.

A 2009 graduate of DePaul University College of Law, Anderson also holds an M.S. in Biotechnology from Illinois State University and a B.S. in Biology from the University of Illinois. Prior to joining RMMS as an associate and becoming a partner, he served as in-house Patent Counsel at the Oklahoma Medical Research Foundation and as a Disease Specialist for Merck & Co., Inc. In 2026, he was part of the RMMS team that accepted the National "Firm of the Year – Life Sciences IP Litigation" award from Managing Intellectual Property.